This inventor holds 2 USPTO granted patents and 2 published patent applications. Top assignees: National Institutes of Biomedical Innovation, Health and Nutrition, Other. Active years: 2021-2025.
Company Filing History:
1 out of 23 
1 out of 834,307 Years Active: 2021-2025
Title: Etsushi Kuroda: Innovator in Immunology
Introduction
Etsushi Kuroda is a prominent inventor based in Suita, Japan. He has made significant contributions to the field of immunology, particularly in the development of novel adjuvants for enhancing immune responses. With a total of 2 patents, Kuroda's work focuses on advancing techniques for anti-cancer and anti-allergic therapies.
Latest Patents
Kuroda's latest patents include a Th1-inducing adjuvant comprising a combination of different nucleic acid adjuvants. This invention aims to induce a novel Th1 response, promoting the activation of cytotoxic T cells and enhancing anti-cancer and anti-allergic activities. The patent details a combination of a CpG oligonucleotide and an STING agonist, which can be used as a type-I adjuvant. Additionally, it describes an anti-cancer agent that combines a CpG oligonucleotide with an STING agonist, as well as a composition that reduces or eliminates the IgE-inducing activity of an STING agonist.
Career Highlights
Throughout his career, Kuroda has worked with the National Institutes of Biomedical Innovation, Health and Nutrition. His research has been pivotal in developing innovative solutions for immune modulation and therapeutic applications.
Collaborations
Kuroda has collaborated with notable colleagues, including Burcu Temizoz and Ken Ishii. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Etsushi Kuroda's innovative work in immunology, particularly through his patents, showcases his commitment to enhancing therapeutic strategies for cancer and allergies. His contributions continue to influence the field and pave the way for future advancements.